Zyn US shipment volume (pouches) in fiscal 2026
Short Answer
The model assigns meaningfully higher odds than the market for Zyn US shipment volume to be Above 10.6 billion, at 94.5% model vs 0.0% market, driven by the FDA's Modified Risk Tobacco Product authorization for 20 Zyn variants and accelerated U.S. investments in the second half of 2026.
1. Executive Verdict
- Zyn shipments likely above 10.8 billion, following FDA Modified Risk authorization.
- Zyn Ultra launch and H2 2026 U.S. investments bolster shipment volumes.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Above 11.6 billion | 50.0% | 77.7% | Model higher by 27.7pp |
| Above 11.8 billion | 52.0% | 56.4% | Model higher by 4.4pp |
| Above 10.8 billion | 93.0% | 94.5% | Model higher by 1.5pp |
| Above 12 billion | 18.0% | 22.0% | Model higher by 4.0pp |
| Above 11.2 billion | 78.0% | 78.7% | Model higher by 0.7pp |
Current Context
Zyn US shipment volumes showed mixed performance in early 2026. U.S. Zyn shipments declined 23.5% year-over-year in the first quarter of 2026, attributed primarily to distributor and retailer inventory normalization [^][^]. In the second quarter of 2026, Philip Morris International (PMI) reported U.S. Zyn shipment volumes of 2.9 billion pouches. This represented a 1.8% year-over-year increase, despite a prior-year inventory tailwind [^][^].
Regulatory approvals and product expansion support Zyn's market position. On June 30, 2026, the FDA granted Modified Risk Tobacco Product (MRTP) authorization to 20 Zyn nicotine pouch variants. This marked the first such authorization for a nicotine pouch product [^][^]. Concurrently, PMI expanded the U.S. Zyn portfolio in June 2026 with the launch of Zyn Ultra (9mg and 11mg variants). The company also plans to introduce additional 1.5mg and 8mg dry variants in the third quarter of 2026 [^][^][^].
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
This market repriced almost instantly, jumping from a 1.0% probability on July 29, 2026, to its current level of 95.0% the following day. This single, sharp upward movement defines the chart's entire history. The move appears to be a direct reaction to Philip Morris International's second-quarter 2026 results. The report of 2.9 billion Zyn pouches shipped in Q2, a 1.8% year-over-year increase, established a strong run-rate for the remainder of the year. This performance seems to have convinced market makers that the full-year target of 10.6 billion pouches is highly probable, overriding concerns from the 23.5% YoY decline reported for Q1.
The most critical technical factor is the complete absence of trading volume. Zero contracts have been traded since the market's inception. This indicates the current price reflects an initial assessment or a market maker's quote rather than a consensus formed through active trading. The lack of volume means no meaningful support or resistance levels have been established. While the 95.0% price signals strong conviction that the shipment target will be met, this sentiment remains untested by capital. The market is effectively illiquid, and the price represents a static estimate pending actual participant activity.
3. Significant Price Movements
Notable price changes detected in the chart, along with research into what caused each movement.
📈 July 29, 2026: 87.0pp spike
Price increased from 1.0% to 88.0%
Outcome: Above 10.8 billion
What happened: The provided research does not identify any specific social media activity from key figures or viral narratives that would explain the 87.0 percentage point spike in the Zyn US shipment volume prediction market on July 29, 2026. While Philip Morris International announced a modest 1.8% year-on-year increase in US ZYN shipment volume for Q2 2026, reaching 3.5 billion pouches, this steady growth does not align with such a significant market movement for the fiscal year 2026 "Above 10.8 billion" outcome [^]. Therefore, based solely on the provided information, social media was not an identifiable driver, and a clear primary driver for this prediction market price movement cannot be determined.
4. Market Data
Contract Snapshot
This market resolves YES if Zyn US shipment volume (pouches) in fiscal 2026 exceeds the specific threshold for each sub-market (e.g., above 11.6 billion), and NO if it is at or below that threshold. Trading begins on February 5, 4:00 PM EST, with a maximum payout date of May 6, 2027. Resolution will be based on the official reported Zyn US shipment volume for fiscal 2026.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Above 10.8 billion | $0.95 | $0.07 | 93% |
| Above 11 billion | $0.92 | $0.15 | 90% |
| Above 11.2 billion | $0.84 | $0.23 | 78% |
| Above 11.4 billion | $0.76 | $0.29 | 76% |
| Above 11.8 billion | $0.35 | $0.72 | 52% |
| Above 11.6 billion | $0.53 | $0.54 | 50% |
| Above 12 billion | $0.23 | $0.83 | 18% |
| Above 10.6 billion | $0.98 | $0.08 | 0% |
Market Discussion
Philip Morris International (PMI) reported U.S. ZYN shipment volumes of 2.9 billion pouches in Q2 fiscal 2026, marking a 1.8% to 2.0% year-on-year increase and a return to growth [^][^][^][^][^]. This followed a Q1 fiscal 2026 volume of 2.3 billion pouches (or 155 million cans), which experienced a 23.5% year-on-year decrease attributed to anticipated distributor inventory normalization [^][^].
5. How is the 2026 launch of Zyn Ultra and other new variants expected to impact Philip Morris International's total U.S. shipment volume?
| Zyn Ultra Launch | June 2026 [^][^][^][^] |
|---|---|
| 2026 Total Volume Target | Broadly stable to slightly growing [^][^][^][^][^][^] |
| Q2 2026 ZYN Shipments | 2.9 billion pouches [^][^] |
PMI launched ZYN Ultra and plans further expansions to bolster its portfolio. Philip Morris International (PMI) introduced ZYN Ultra in June 2026, featuring 9mg and 11mg moist variants, as a strategic move to defend market share, align with competitor pricing, and address portfolio gaps in the high-intensity segment [^][^][^][^]. While management noted the early nature of the data, initial results for ZYN Ultra have shown sequential growth and positive consumer feedback [^][^]. The company is also set to expand its ZYN portfolio further in Q3 2026 with 1.5mg and 8mg dry variants, alongside accelerating U.S. investments in the latter half of the year to enhance brand equity and category competitiveness [^][^][^].
New ZYN variants and investments aim for stable 2026 shipment volumes. The introduction of ZYN Ultra and other new variants, coupled with accelerated U.S. investments, is anticipated to support PMI's objective of achieving broadly stable to slightly growing total volumes in 2026 [^][^][^][^][^][^]. These initiatives are integral to the company's ambition for its sixth consecutive year of total volume growth [^][^]. In the second quarter of 2026, PMI reported ZYN shipments totaling 2.9 billion pouches, marking a 1.8% to 2% year-on-year increase despite the presence of inventory tailwinds in the prior year [^][^].
6. How has Zyn's U.S. market share in the nicotine pouch category evolved in 2026 compared to its primary competitors, Velo and On!?
| Zyn Q2 2026 U.S. Shipments | 2.9 billion pouches [^][^][^] |
|---|---|
| Zyn Q2 2026 U.S. Shipment Growth | 2% year-over-year increase [^][^][^] |
| Zyn Q1 2026 U.S. Shipment Change | 23.5% fall [^][^][^] |
Zyn retained market leadership amid rising competition in 2026. Zyn maintained its dominant position in the U.S. nicotine pouch market in 2026, despite facing increased pressure from competitors, particularly Velo Plus [^][^][^][^]. Velo Plus gained ground by offering moister pouches and more competitive pricing [^]. However, specific aggregated 2026 U.S. market share percentage data directly comparing Zyn, Velo, and On! is not currently available in the searched sources [^].
Zyn's shipment volume recovered, prompting a strategic product launch. Philip Morris International reported shipping 2.9 billion Zyn pouches in the U.S. during Q2 2026, representing a 2% year-over-year increase [^][^][^]. This Q2 performance indicated a recovery for the brand, as U.S. shipments had previously fallen by 23.5% in a challenging Q1 2026 [^][^][^]. In response to competitive pressure from moister and lower-priced products, Philip Morris International launched Zyn Ultra in the U.S. in June 2026 [^][^]. This new offering features a moist, 20-pouch-per-can format, a strategic shift from Zyn's traditional dry-pouch, 15-count offering [^][^].
7. What do industry reports and PMI guidance indicate about Zyn's distributor inventory levels after the Q1 2026 normalization?
| Q1 2026 ZYN Shipments Decline | 23.5% to 2.3 billion pouches (155 million cans) [^][^][^] |
|---|---|
| Inventory Normalization | Broadly normalized by end of Q1 2026 [^][^][^] |
| Q2 2026 ZYN Shipments Increase | 1.8% year-on-year to 2.9 billion pouches [^][^][^] |
ZYN shipments significantly declined in Q1 2026 due to inventory normalization. During this quarter, ZYN shipments dropped by 23.5%, totaling 2.3 billion pouches or 155 million cans. This decrease was a direct consequence of the adjustment of distributor and trade inventory levels, which Philip Morris International confirmed were broadly normalized by the close of Q1 2026 [^][^][^].
Following normalization, ZYN shipments rebounded in Q2 2026, aligning with consumer demand. Shipments increased by 1.8% year-on-year to 2.9 billion pouches, despite the absence of a prior-year inventory tailwind. This Q2 growth was consistent with stable to slightly growing consumer offtake trends. The overall 2026 ZYN US shipment volume trajectory indicates a strong rebound in Q2 after the initial Q1 inventory correction, with PMI's business performance and investment plans for the latter half of 2026 focused on maximizing the brand's long-term growth post-normalization [^][^][^][^][^].
8. Which retail scanner data providers offer the most timely insights into Zyn's U.S. sales velocity in 2026?
| Q1 2026 Zyn U.S. Shipment Volume Consensus | 183-185 million cans [^][^][^] |
|---|---|
| Full-Year 2026 Zyn U.S. Shipment Volume Projection | Exceed 700 million cans [^][^][^] |
| Primary Data Aggregators for Scan Data | KDP (Management Science Associates) and MSA [^] |
Multiple data providers offer critical insights into Zyn's U.S. sales velocity. Financial firms and investment analysts regularly monitor Zyn's U.S. sales performance, frequently relying on scanner data from providers such as Nielsen, which is often cited by major financial institutions [^][^]. For more timely and granular insights into Zyn and other CPG brands, specialized alternative data providers, including Consumer Edge, Earnest Analytics, and Retail Velocity, offer high-frequency point-of-sale (POS) and consumer transaction data collected from thousands of retail locations [^][^][^]. These resources enable detailed assessments of Zyn's U.S. sales velocity.
Retailer-submitted scan data forms the basis for market analytics and projections. Aggregators like KDP (Management Science Associates) and MSA act as primary collection points for retailer-submitted scan data, which is crucial for manufacturer rebate programs and provides the foundational transactional information leveraged by broader market analytics providers [^]. Based on this data, market consensus for Zyn's U.S. shipment volume in Q1 2026 centered around 183-185 million cans, with total full-year 2026 projections anticipated to surpass 700 million cans [^][^][^].
9. What potential state-level regulations or federal FDA actions could materially affect Zyn's sales velocity in late 2026?
| FDA ZYN MRTP Grant Date | June 30, 2026 [^][^][^] |
|---|---|
| NY Proposed Nicotine Pouch Tax | 75% wholesale rate [^][^][^][^] |
| Number of ZYN MRTP Products | 20 products [^][^][^] |
The U.S. Food and Drug Administration granted Zyn nicotine pouches modified risk marketing status. On June 30, 2026, the FDA issued Modified Risk Tobacco Product (MRTP) orders for 20 ZYN nicotine pouch products. This action permits these products to be marketed with claims of reduced disease risk compared to cigarettes [^][^][^]. The FDA acknowledged that obtaining nicotine through the mouth bypasses the harm caused by the inhalation of carbons [^].
State and local regulations threaten Zyn's sales velocity through taxes and bans. Potential state-level regulations and ongoing local bans could materially affect sales velocity. For instance, New York's Governor Kathy Hochul proposed an executive budget plan in July 2026 to tax nicotine pouches at a 75% wholesale rate, similar to cigarettes [^][^][^][^]. However, the legislative outcome for this specific proposal remained uncertain during the first half of the year [^]. Additionally, local regulatory actions, such as Massachusetts municipal bans on certain flavored tobacco and nicotine products, continue to create fragmented market access issues that can influence localized sales [^].
10. What Could Change the Odds
Key Catalysts
U.S. ZYN shipments saw a Q2 2026 increase of 1.8% to 2.9 billion pouches, recovering from a 23.5% decline in Q1 2026 attributed to inventory adjustments [^]. A significant bullish catalyst emerged on June 30, 2026, when the FDA granted Modified Risk Tobacco Product (MRTP) authorization to 20 ZYN variants, marking the first such authorization for a nicotine pouch [^][^][^]. This FDA action supports brand differentiation and long-term brand equity [^][^][^].
Philip Morris International is accelerating U.S. investments in the second half of 2026 to support the expanded ZYN portfolio, including the ZYN ULTRA variants launched in June, and to prepare for the future launch of IQOS ILUMA [^][^]. Despite these investments, bearish factors for 2026 include intensifying competition, regulatory uncertainty regarding flavored products, and potential price sensitivity [^]. The company has also faced repeated cuts to annual profit forecasts due to currency impacts [^][^][^].
Key Dates & Catalysts
- Expiration: May 06, 2027
- Closes: May 06, 2027
11. Decision-Flipping Events
- Trigger: U.S.
- Trigger: ZYN shipments saw a Q2 2026 increase of 1.8% to 2.9 billion pouches, recovering from a 23.5% decline in Q1 2026 attributed to inventory adjustments [^] .
- Trigger: A significant bullish catalyst emerged on June 30, 2026, when the FDA granted Modified Risk Tobacco Product (MRTP) authorization to 20 ZYN variants, marking the first such authorization for a nicotine pouch [^] [^] [^] .
- Trigger: This FDA action supports brand differentiation and long-term brand equity [^] [^] [^] .
13. Historical Resolutions
Historical Resolutions: 8 markets in this series
Outcomes: 0 resolved YES, 0 resolved NO
Recent resolutions:
- KXPMA-28JANZYN-820000000: SCALAR (Jul 27, 2026)
- KXPMA-28JANZYN-800000000: SCALAR (Jul 27, 2026)
- KXPMA-28JANZYN-780000000: SCALAR (Jul 27, 2026)
- KXPMA-28JANZYN-760000000: SCALAR (Jul 27, 2026)
- KXPMA-28JANZYN-740000000: SCALAR (Jul 27, 2026)
